Sector: Biotechnology

October 21, 2022

From the G 2/21 preliminary opinion.

Plausibility: Insights from the G 2/21 preliminary opinion The EPO’s Enlarged Board of Appeal (EBA) referral G 2/21 will hopefully clarify the

January 11, 2022

Plausibility and Post-Published Evidence (G2/21).

The Enlarged Board of Appeal of the European Patent Office has been challenged with a new referral (G2/21) concerning the admissibility of

March 21, 2021

EPO Guidelines for Examination: Patentability of antibodies

The latest changes to the EPO Guidelines for Examination provide several updates to (i) the patent protection of antibodies, and (ii) the interpretation

March 8, 2021

Updates to the EPO Guidelines for Examination: Patentability of plants and animals, human-derived cells, and methods of treatment by therapy

The latest changes to the EPO Guidelines for Examination provide several updates in relation to the patent protection of (i) plants and

June 4, 2020

The EPO rules that plants and animals exclusively obtained by essentially biological processes are not patentable

The Enlarged Board of Appeal (EBA) of the EPO has confirmed in decision G3/19 that plants, plant material or animals exclusively obtained